Drug intelligence / Profile preview

aAPC-NK002

Development stage: Preclinical
Lead developer: Shanghai YaKe Biotechnology
Modality: Cell Therapies
Administration: Intravenous

Overview

aAPC-NK002 is a preclinical-stage artificial antigen-presenting cell (aAPC) technology developed by YaKe Biotechnology for the ex vivo expansion and activation of natural killer (NK) cells. The platform is designed to enhance the cytotoxic activity of NK cells against cancer cells. In vitro studies have demonstrated that NK cells expanded using the aAPC-NK002 system exhibit potent tumor-killing activity against A549 lung cancer cells. The technology is being developed for applications in cancer prevention, immune enhancement, and oncology.

Targets

NKG2D (Natural killer group 2 member D receptor)IL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)TNFRSF9 (CD137 extracellular domain)IL21R (Interleukin-21 receptor)

Beyond the preview

Go deeper on aAPC-NK002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on aAPC-NK002.

Explore the full profile